de Heer, E. C.
Zois, C. E.
Bridges, E.
van der Vegt, B.
Sheldon, H.
Veldman, W. A.
Zwager, M. C.
van der Sluis, T.
Haider, S.
Morita, T.
Baba, O.
Schröder, C. P.
de Jong, S.
Harris, A. L.
Jalving, M.
Funding for this research was provided by:
Breast Cancer Research Foundation
Cancer Research UK
Nijbakker-Morra Stichting
Stichting Jo Kolk Studiefonds
Stichting de Drie Lichten
Stichting De Cock-Hadders
Groninger Universiteitsfonds
Junior Scientific Masterclass (MD-PhD 17-53)
Article History
Received: 23 December 2022
Accepted: 18 May 2023
First Online: 6 June 2023
Change Date: 28 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13046-023-02800-3
Declarations
:
: The local institutional board of the University Medical Center Groningen waived the need for informed consent (nr 201900243) for use of patient tissue in the TMA. The non-objection registry verified that none of the included patients objected against the use of their medical data for research. Animal experiments were approved by the institutional review board at the University of Oxford and under a Home Office license (license number 30–3197).
: Not applicable.
: BvdV is on the scientific advisory board, does consultancy for Visiopharm, Philips, MSD/Merck, AstraZeneca, Daiichi Sankyo and has received speaker’s fee from Visiopharm, Diaceutics, MSD/Merck (all honoraria received by UMCG). CPS is supported by the Dutch Cancer Society, unrestricted research grants from Siemens, Pfizer and support for clinical trials by Roche, Seagen. ALH and CEZ are supported by grants from the Breast Cancer Research Foundation. MJ is on the advisory board for Merck, BMS, Novartis, Pierre Fabre, AstraZeneca (honoraria to the institution). Clinical studies: BMS, Merck. The other authors have no competing interests to report.